Video

Dr. Bendell on using OMP-59R5 to treat Pancreatic Cancer

Author(s):

Johanna Bendell, MD

In Partnership With:

Johanna Bendell, MD, director of GI Cancer Research Program, associate director, Drug Development Program, Sarah Cannon Research Institute, discusses the anti-cancer stem cell antibody OMP-59R5 as a treatment option for patients with metastatic pancreatic cancer.

Johanna Bendell, MD, director of GI Cancer Research Program, associate director, Drug Development Program, Sarah Cannon Research Institute, discusses the anti-cancer stem cell antibody OMP-59R5 as a treatment option for patients with metastatic pancreatic cancer.

Bendell says there are many new advances for patients with metastatic pancreatic cancer. At first, there were advances in chemotherapy regimens but the focus has shifted to targeted agents.

At the 2014 Gastrointestinal Cancers Symposium in San Francisco, data was presented on OMP-59R5 in combination with nab-paclitaxel and gemcitabine for patients with untreated metastatic pancreatic cancer. Bendell says this agent targets the stem cells that stay living in pancreatic cancer even after the cancer has been attacked with chemotherapy. These stem cells are important to target as they repopulate cancer cells.

Related Videos
Alastair Thompson, BSc, MBChB, MD, FRCS
C. Ola Landgren, MD, PhD
Sara M. Tolaney, MD, MPH
Adam M. Brufsky, MD, PhD, FACP
Justin M. Watts, MD
Sara M. Tolaney, MD, MPH
Leah Backhus, MD, MPH, FACS, professor, University Medical Line, Cardiothoracic Surgery, co-director, Thoracic Surgery Clinical Research Program, associate program director, Thoracic Track, CT Surgery Residency Training Program, Thelma and Henry Doelger Professor of Cardiovascular Surgery, Stanford Medicine; chief, Thoracic Surgery, VA Palo Alto
Roy S. Herbst, MD, PhD, Ensign Professor of Medicine (Medical Oncology), professor, pharmacology, deputy director, Yale Cancer Center; chief, Medical Oncology, director, Center for Thoracic Cancers, Yale Cancer Center and Smilow Cancer Hospital; assistant dean, Translational Research, Yale School of Medicine
Chirag Shah, MD
Jason A. Mouabbi, MD
Related Content
Shubham Pant, MD, MBBS
July 24th 2024

Zanidatamab Demonstrates Activity in Pretreated HER2+ Biliary Tract Cancer

Stephen Liu, MD; Sara A. Hurvitz, MD, FACP; S. Vincent Rajkumar, MD; Sumanta Kumar Pal, MD, FASCO; Shubham Pant, MD, MBBS
May 23rd 2024

Oncology Experts Preview Top Abstracts From the 2024 ASCO Annual Meeting

Tanios S. Bekaii-Saab, MD, FACP, of the Mayo Clinic
July 19th 2024

Complexity in GI Cancer: Questions Are Answered in Gastroesophageal Cancer, Remain in HCC

Ian Flinn, MD, PhD; Nicole Lamanna, MD; Jennifer R. Brown, MD, PhD; Constantine Tam, MD, MBBS
February 16th 2023

FDA Approval Insights: Zanubrutinib in CLL and SLL

The FDA has granted fast track designation to CT-0525 for the treatment of patients with HER2-overexpressing solid tumors.
July 14th 2024

FDA Awards Fast Track Designation to CT-0525 for HER2-Overexpressing Solid Tumors

Ciara Kelly, MBBCh, BAO
July 13th 2024

Innovative Research Continues to Propel Individualized GIST Treatments